HealthDay News — According to a recommendation statement from the US Preventive Services Task Force (USPSTF), published in JAMA, pre-eclampsia screening with blood pressure measurements during pregnancy is recommended.
Kirsten Bibbins-Domingo, PhD, MD, from the University of California, San Francisco, and colleagues from the USPSTF reviewed the evidence on the accuracy of screening and diagnostic tests for pre-eclampsia and the benefits and harms of screening and treatment of screen-detected pre-eclampsia in order to update the 1996 recommendation.
The researchers note that there was adequate evidence that pre-eclampsia screening results in considerable benefit for mother and infant, given that treatment can reduce maternal and perinatal morbidity and mortality and the established accuracy of measuring blood pressure.
Sufficient evidence also suggested that screening for and treatment of pre-eclampsia was associated with potential harms that were no greater than small.
Based on these findings, the USPSTF concluded that there is substantial net benefit of pre-eclampsia screening in pregnant women (B recommendation).
“Pre-eclampsia can progress quickly and lead to severe complications for both the mother and infant,” task force member Maureen Phipps, MD, MPH, said in a statement. “It is critical that women be screened for pre-eclampsia during every clinical visit throughout their pregnancy.”
Henderson JT, et al. “Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA. 2017;317(16): 1668-1683. doi:10.1001/jama.2016.18315
Sperling JD and Gossett DR. “Screening for Preeclampsia and the USPSTF Recommendations.” JAMA. 2017;317(16): 1629-1630. doi:10.1001/jama.2017.2018
“US Preventive Services Task Force. Screening for Preeclampsia: US Preventive Services Task Force | Recommendation Statement.” JAMA. 2017;317(16): 1661-1667. doi:10.1001/jama.2017.3439